Cargando…

LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis

Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discover...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Linjun, Yang, Yuquan, Li, Mengying, Li, Chenxi, Zhou, Zengtong, Tang, Guoyao, Wu, Lan, Yao, Yilin, Shen, Xuemin, Hou, Zhaoyuan, Jia, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077312/
https://www.ncbi.nlm.nih.gov/pubmed/35051616
http://dx.doi.org/10.1016/j.ymthe.2022.01.003
_version_ 1784702094489419776
author Shi, Linjun
Yang, Yuquan
Li, Mengying
Li, Chenxi
Zhou, Zengtong
Tang, Guoyao
Wu, Lan
Yao, Yilin
Shen, Xuemin
Hou, Zhaoyuan
Jia, Hao
author_facet Shi, Linjun
Yang, Yuquan
Li, Mengying
Li, Chenxi
Zhou, Zengtong
Tang, Guoyao
Wu, Lan
Yao, Yilin
Shen, Xuemin
Hou, Zhaoyuan
Jia, Hao
author_sort Shi, Linjun
collection PubMed
description Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC.
format Online
Article
Text
id pubmed-9077312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-90773122023-04-06 LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis Shi, Linjun Yang, Yuquan Li, Mengying Li, Chenxi Zhou, Zengtong Tang, Guoyao Wu, Lan Yao, Yilin Shen, Xuemin Hou, Zhaoyuan Jia, Hao Mol Ther Original Article Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC. American Society of Gene & Cell Therapy 2022-04-06 2022-01-17 /pmc/articles/PMC9077312/ /pubmed/35051616 http://dx.doi.org/10.1016/j.ymthe.2022.01.003 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Shi, Linjun
Yang, Yuquan
Li, Mengying
Li, Chenxi
Zhou, Zengtong
Tang, Guoyao
Wu, Lan
Yao, Yilin
Shen, Xuemin
Hou, Zhaoyuan
Jia, Hao
LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
title LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
title_full LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
title_fullStr LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
title_full_unstemmed LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
title_short LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
title_sort lncrna ifitm4p promotes immune escape by up-regulating pd-l1 via dual mechanism in oral carcinogenesis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077312/
https://www.ncbi.nlm.nih.gov/pubmed/35051616
http://dx.doi.org/10.1016/j.ymthe.2022.01.003
work_keys_str_mv AT shilinjun lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT yangyuquan lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT limengying lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT lichenxi lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT zhouzengtong lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT tangguoyao lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT wulan lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT yaoyilin lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT shenxuemin lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT houzhaoyuan lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis
AT jiahao lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis